The 2025 Pierre Galletti Award, the American Institute for Medical and Biological Engineering’s highest award, was given on March 30 to Jennifer L. West, dean of the UVA School of Engineering and Applied Science.

A collaborative research effort in global childhood cancer has revealed the significant negative impact of living in regions of armed conflict on pediatric cancer outcomes.

Public awareness of the link between drinking alcohol and an elevated risk of cancer has grown since last fall, with 55% of U.S. adults saying that regularly consuming alcohol increases your chances of later developing cancer, according to a survey by the Annenberg Public Policy Center.

Medical imaging experts are adept at solving common optical illusions, according to UEA research.

The research is the first to show that people can be trained to do better at solving visual illusions, which was previously thought to be near-impossible.

The study shows that medical imaging experts are particularly accurate at judging the size of objects in common optical illusions. In other words, they also literally see better in everyday life!

A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team identified a monoclonal antibody called KG2032 that reacts with a certain variant of the HLA-DRB1 molecule. KG2032 CAR T cells displayed strong anti-AML effects in a mouse model, and CAR natural killer cells showed similar results. Clinical trials are currently being planned. 

A pan-Canadian team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumours in chicken eggs and analyzing their proteins. The team, led by researchers from the University of British Columbia and BC Children’s Hospital Research Institute, is the first in Canada to combine these two techniques to identify and test a drug for a young patient's tumour in time to be used for their treatment. Their success in finding a new drug for the patient, described today in EMBO Molecular Medicine, shows how the study of proteins, known as proteomics, can be a valuable complement to the established study of genes (genomics) in real-time cancer therapies.